Pacira BioSciencesFRA:82P +2.75%75 Return-on-Tangible-Equity is 4.01% as of Mar. 2026, which is 309% above its 10-year median of 0.98. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 897 Drug Manufacturers companies, Pacira BioSciences ranks worse than 67.56% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pacira BioSciences's annualized net income for the quarter that ended in Mar. 2026 was €10.1 Mil. Pacira BioSciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €251.6 Mil. Therefore, Pacira BioSciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.01%.
The historical rank and industry rank for Pacira BioSciences's Return-on-Tangible-Equity or its related term are showing as below:
FRA:82P'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -34.57 Med: 0.98 Max: 97.94
Current: 1.64
During the past 13 years, Pacira BioSciences's highest Return-on-Tangible-Equity was 97.94%. The lowest was -34.57%. And the median was 0.98%.
FRA:82P's Return-on-Tangible-Equity is ranked worse than 67.56% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs FRA:82P: 1.64
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Pacira BioSciences Return-on-Tangible-Equity Related Terms
Pacira BioSciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.01% mean?
Pacira BioSciences (FRA:82P) has a Return-on-Tangible-Equity of 4.01% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pacira BioSciences and its competitors. This is 309% above median its historical median of 0.98. According to the industry distribution chart, Pacira BioSciences ranks #606 out of 897 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Pacira BioSciences' Return-on-Tangible-Equity too high?
Pacira BioSciences' current Return-on-Tangible-Equity of 4.01% is 309% above median its 10-year median of 0.98. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Pacira BioSciences' value of 4.01% is 49.2% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #606 out of 897 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Return-on-Tangible-Equity compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #606 out of 897 companies for Return-on-Tangible-Equity. This places Pacira BioSciences in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Pacira BioSciences' value of 4.01% is 49.2% below this benchmark. While the company's 10-year median is 0.98 vs. the industry median of 7.90, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Return-on-Tangible-Equity of 4.01% is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Return-on-Tangible-Equity is 4.01%, which is 309% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Return-on-Tangible-Equity of 4.01%. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Return-on-Tangible-Equity is 4.01%, which is 309% above median its 10-year median of 0.98 and 49.2% below the Drug Manufacturers industry median of 7.90. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Return-on-Tangible-Equity is 4.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.
Key valuation signals for FRA:82P:
Return-on-Tangible-Equity: 4.01% (309% above median its 10-year median of 0.98)
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
Industry Position: 49.2% below the Drug Manufacturers median (#606 of 897)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for FRA:82P
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
